Evidence-based Anticancer Materia Medica for Cervical Cancer

2011 ◽  
pp. 129-150
Author(s):  
Tatjana Stanojković ◽  
Aleksandra Konić-Ristić ◽  
Teodora Janković ◽  
Gordana Zdunić ◽  
Katarina Šavikin
Keyword(s):  
Cervical Cancer ◽  
Evidence Based ◽  
Materia Medica

Cancer screening. Current state of the problem

2020 ◽  
pp. 4-12
Author(s):  
Marina Kochiyeva
Keyword(s):  
Breast Cancer ◽  
Cervical Cancer ◽  
Colon Cancer ◽  
Cancer Screening ◽  
Target Population ◽  
Evidence Based ◽  
Screening Programs ◽  
Current State ◽  
Methodological Approaches ◽  
Based Medicine

Data on modern methodological approaches that are used in screening for cancer are summarized. General principles of organizing screening studies are examined from the perspective of evidence-based medicine, target population, research methods, and effectiveness of the implemented screening programs for breast cancer, cervical cancer, and colon cancer are determined.

scholarly journals Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings

2017 ◽  
Vol 6 (8) ◽  
pp. 2008-2014 ◽  
Author(s):  
Nicole G. Campos ◽  
Vivien Tsu ◽  
Jose Jeronimo ◽  
Mercy Mvundura ◽  
Jane J. Kim
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Evidence Based ◽  
Low Resource Settings ◽  
Screening Programs ◽  
Low Resource ◽  
Policy Choices ◽  
Evidence Based Policy

scholarly journals Critical Appraisal on the Selection Criteria for Evidence-based Healthcare

2021 ◽  
Author(s):  
Paulo Cesar Morales Mayer ◽  
Caroline Amélia Gonçalves ◽  
Franz Porzsolt
Keyword(s):  
Cervical Cancer ◽  
Clinical Trials ◽  
Selection Criteria ◽  
Human Subjects ◽  
Evidence Based ◽  
Inclusion Criteria ◽  
Pragmatic Trials ◽  
Exclusion Criteria ◽  
Policy Makers ◽  
Evidence Based Healthcare

Abstract Background: Evidence-Based healthcare deals basically with published clinical trials to guide the decision making on what treatment to use for any specific conditions.Aims: The present paper assessed the inclusion and exclusion criteria used in clinical trials of cervical cancer aiming at establishing a clear distinction between each criterion.Methods: We performed a bibliographical search in pubmed with the terms cervical cancer and treatment or therapy filtered for clinical trials with human subjects for the last ten years. A total of 30 papers were used extracting and classifying the inclusion and exclusion category according to the characteristic they described. Results: We found no clear parameter to establish which criteria could exclusively serve as inclusion or exclusion across the papers, about 56% of the categories identified were found either listed as inclusion or exclusion criteria or even as both in some cases.Conclusions: The key issue of selection criteria is not in its form but in its function, the first point to consider is if the trial is experimental (focused on efficacy and proof of principle) or observational (pragmatic trials, focused on effectiveness and real world conditions). We suggest, inclusion criteria should be broad, focused on the investigated condition; exclusion criteria should apply only to the subset of this “included” population, and do not take part in observational studies. These conclusions do not serve only for researchers but should affect practitioners and policy makers to correctly compare the results of investigated treatment.

Evidence-based Anticancer Materia Medica for Lymphoma

2011 ◽  
pp. 171-194
Author(s):  
Eran Ben-Arye ◽  
Tamar Tadmor ◽  
Aaron Polliack ◽  
Elad Schiff
Keyword(s):  
Evidence Based ◽  
Materia Medica

Evidence-based Anticancer Materia Medica for Prostate Cancer

2011 ◽  
pp. 103-127
Author(s):  
Yi-Ren Chen ◽  
Pei-Wen Hsiao ◽  
Feng-Ming Lin ◽  
Guan-James Wu ◽  
Chin-Hsien Tsai
Keyword(s):  
Prostate Cancer ◽  
Evidence Based ◽  
Materia Medica

scholarly journals The SUCCEED Legacy Grant Program: Enhancing Community Capacity to Implement Evidence-Based Interventions in Breast and Cervical Cancer

2012 ◽  
Vol 23 (2A) ◽  
pp. 62-76
Author(s):  
John Harvey Wingfield ◽  
Tabia Henry Akintobi ◽  
DeBran Jacobs ◽  
Marvella E. Ford
Keyword(s):  
Cervical Cancer ◽  
Community Capacity ◽  
Evidence Based ◽  
Breast And Cervical Cancer ◽  
Grant Program

Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer

2020 ◽  
Vol 30 (4) ◽  
pp. 311-327 ◽  
Author(s):  
Kari Tanderup ◽  
Nicole Nesvacil ◽  
Kathrin Kirchheiner ◽  
Monica Serban ◽  
Sofia Spampinato ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Locally Advanced ◽  
Evidence Based ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Image Guided ◽  
Dose Planning

scholarly journals From potential to practice: how accelerating access to HPV tests and screen and treat programmes can help eliminate cervical cancer

2019 ◽  
Vol 7 (4) ◽  
pp. e000182
Author(s):  
William Cherniak ◽  
Nikki Tyler ◽  
Kriti Arora ◽  
Ilana Lapidos-Salaiz ◽  
Emma Sczudlo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
International Development ◽  
New Technologies ◽  
Hpv Vaccination ◽  
Evidence Based ◽  
User Research ◽  
Cancer Screen ◽  
Hpv Test ◽  
Vaccination Campaigns ◽  
Cervical Cancer Screen

Human papillomavirus (HPV) vaccination campaigns to prevent cervical cancer are being considered and implemented in countries around the world. While vaccination will protect future generations, it will not help the millions of women currently infected, leading to an estimated 311 000 deaths per year globally. This paper examines a selection of strategies that when applied to both existing and new technologies, could accelerate access to HPV testing. Authors from the US Agency for International Development, the National Institutes of Health, and the Bridge to Health Medical and Dental, a non-governmental organisation, joined forces to propose a scalable and country-directed solution for preventing cervical cancer using an end-to-end approach. Collectively, the authors offer seven evidence-based strategies, that when used alone or in combination have the ability to reduce HPV-caused cervical cancer deaths and disability. These strategies include (1) consistent HPV test intervals to decrease HPV DNA test costs; (2) exploring market shaping opportunities; (3) employing iterative user research methodologies like human-centred design; (4) target product profiles for new HPV tests; (5) encouraging innovation around cervical cancer screen and treat programmes; (6) developing national cancer control plans; and (7) integrating cervical cancer screen and treat services into existing infrastructure. By using the strategies outlined here, in combination with HPV vaccination campaigns, national governments will be able to scale and expand cervical cancer screening programmes and provide evidence-based treatment programmes for HPV-infected women.

Evidence-Based Therapy for Recurrent Cervical Cancer

2014 ◽  
Vol 32 (25) ◽  
pp. 2687-2690 ◽  
Author(s):  
Bradley J. Monk ◽  
Krishnansu S. Tewari
Keyword(s):  
Cervical Cancer ◽  
Evidence Based ◽  
Recurrent Cervical Cancer ◽  
Evidence Based Therapy
Sign in / Sign up

Export Citation Format

Share Document